The Life Sciences and Special Purpose Acquisition Companies teams guided BridgeBio Oncology Therapeutics, Inc. (“BBOT”) on the closing of its previously announced business combination with Helix Acquisition Corp. II, a special purpose acquisition company (SPAC) sponsored by affiliates of Cormorant Asset Management. In connection with the closing, Helix changed its name to “BridgeBio Oncology Therapeutics, Inc.”, and beginning on August 12, 2025, the shares of common stock of the combined company began trading under the new ticker symbol “BBOT” on the Nasdaq Global Market.
The combined business is expected to have approximately $490 million in cash, cash equivalents and marketable securities consisting of BBOT’s cash, cash equivalents and marketable securities of approximately $130 million and net proceeds of approximately $365 million reflecting proceeds of approximately $120 million from the former Helix Trust account, proceeds of $261 million from PIPE investors, and the deduction of approximately $15 million in offering expenses.
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.
The Goodwin team was led by Maggie Wong, Jocelyn Arel, Justin Anslow, Alicia Tschirhart, Swetha Gopalakrishnan, Yifeng Yuan, Leon Levman, Candace Rue Hagey, Grace Wirth, Rahat Tariq, Julie Tibbets, Elizabeth Mulkey, Matthew Wetzel, Dan Karelitz, Shlomo Gottesman, Justin Pierce, Gozde Guckaya, Simone Waterbury, Jacquelyn Burke, Brian Mukherjee, Jonathan Shapiro, Hayes Hyde, Natasha Daughtrey, Christina Ademola, Andrew Hudlow, Michael Casaburi, Jim Matarese, Folake Ayoola, Ettore Santucci and Mark Burnett with invaluable help from Noelle Dubiansky, Kimberley Maruncic, Dan Liu, Tricia Hojo and Ruowen Li.